Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 11/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8226327 | 0.89 | KMT2A (0.56) | KMT2AMEN1 | |
| SCHEMBL4654602 | 0.89 | KMT2A (0.45) | VCPKMT2AMEN1 | |
| SCHEMBL4654689 | 0.82 | KMT2A (0.48) | KMT2AMEN1 | |
| SCHEMBL914468 | 0.81 | KMT2A (0.45) | VCPHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL914469 | 0.81 | KMT2A (0.45) | VCPHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8291594 | 0.80 | TDP1 (0.47) | KMT2AMEN1 | |
| SCHEMBL915910 | 0.80 | KMT2A (0.43) | VCPHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL915909 | 0.80 | KMT2A (0.43) | VCPHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL915159 | 0.78 | VCP (0.43) | VCPKMT2AMEN1 | |
| SCHEMBL915160 | 0.78 | VCP (0.43) | VCPKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1602354-B1 | Use of polyglutamic acid or its salts | MEIJI SEIKA KAISHA (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | CUTA, COL14A1, PRKDC | VCP 4813/4885HDAC3 727/4885HDAC4 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.